Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus cisplatin versus TPF induction chemotherapy before concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma
ChiCTR1800019922Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel, cisplatin, docetaxel and fluorouracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Failure-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
nab-paclitaxelcisplatindocetaxelfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800019922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019922.